Linked Data API

Show Search Form

Search Results

390468
unstar this property registered interest false more like this
star this property date less than 2015-07-15more like thismore than 2015-07-15
star this property answering body
Department for Transport more like this
star this property answering dept id 27 more like this
star this property answering dept short name Transport more like this
star this property answering dept sort name Transport more like this
star this property hansard heading Large Goods Vehicles more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Transport, if his Department will make an assessment of whether the powers local councils and police have to enforce restrictions on heavy goods vehicles driving on weight-restricted roads are sufficient to protect rural roads and surrounding environments. more like this
star this property tabling member constituency Mid Derbyshire remove filter
star this property tabling member printed
Pauline Latham remove filter
star this property uin 7365 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2015-07-20more like thismore than 2015-07-20
star this property answer text <p>All road users benefit from clear directions, including HGV drivers. It is clearly not in the interests of HGV drivers to rely upon inaccurate information, which may make them late or even involve them in accidents. Nevertheless, we believe that legislation would be a costly, bureaucratic and inappropriate way of dealing with the problem. Instead we have made significant efforts to link together freight associations, local authorities and satnav companies to ensure that HGV drivers are aware of the issue and have the latest information available to them.</p><p> </p><p> </p><p> </p><p>Councils already have the means to set height and weight restrictions for roads, which are enforced by the police, and HGV satnav devices increasingly include up-to-date routing information that takes account of such restrictions.</p><p> </p><p> </p><p> </p><p>Decisions on all aspects of traffic management policy are the responsibility of local traffic authorities, and how they and the police enforce this once they are in place it is a matter for them. We believe the necessary enforcement powers are available for this.</p><p> </p>
star this property answering member constituency Harrogate and Knaresborough more like this
star this property answering member printed Andrew Jones more like this
unstar this property grouped question UIN 7366 more like this
star this property question first answered
less than 2015-07-20T14:46:34.793Zmore like thismore than 2015-07-20T14:46:34.793Z
unstar this property answering member
3996
star this property label Biography information for Andrew Jones more like this
star this property tabling member
4025
star this property label Biography information for Mrs Pauline Latham more like this
390466
unstar this property registered interest false more like this
star this property date less than 2015-07-15more like thismore than 2015-07-15
star this property answering body
Department for Transport more like this
star this property answering dept id 27 more like this
star this property answering dept short name Transport more like this
star this property answering dept sort name Transport more like this
star this property hansard heading Large Goods Vehicles more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Transport, if his Department will bring forward legislative proposals to require heavy goods vehicles satellite navigation system providers to remove weight-restricted roads from their routes. more like this
star this property tabling member constituency Mid Derbyshire remove filter
star this property tabling member printed
Pauline Latham remove filter
star this property uin 7366 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2015-07-20more like thismore than 2015-07-20
star this property answer text <p>All road users benefit from clear directions, including HGV drivers. It is clearly not in the interests of HGV drivers to rely upon inaccurate information, which may make them late or even involve them in accidents. Nevertheless, we believe that legislation would be a costly, bureaucratic and inappropriate way of dealing with the problem. Instead we have made significant efforts to link together freight associations, local authorities and satnav companies to ensure that HGV drivers are aware of the issue and have the latest information available to them.</p><p> </p><p> </p><p> </p><p>Councils already have the means to set height and weight restrictions for roads, which are enforced by the police, and HGV satnav devices increasingly include up-to-date routing information that takes account of such restrictions.</p><p> </p><p> </p><p> </p><p>Decisions on all aspects of traffic management policy are the responsibility of local traffic authorities, and how they and the police enforce this once they are in place it is a matter for them. We believe the necessary enforcement powers are available for this.</p><p> </p>
star this property answering member constituency Harrogate and Knaresborough more like this
star this property answering member printed Andrew Jones more like this
unstar this property grouped question UIN 7365 more like this
star this property question first answered
less than 2015-07-20T14:46:34.697Zmore like thismore than 2015-07-20T14:46:34.697Z
unstar this property answering member
3996
star this property label Biography information for Andrew Jones more like this
star this property tabling member
4025
star this property label Biography information for Mrs Pauline Latham more like this
657124
unstar this property registered interest false more like this
star this property date less than 2016-12-12more like thismore than 2016-12-12
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Skin Cancer: Medical Treatments more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Health, what restrictions have been placed on patients accessing treatments for advanced (stage 4) melanoma by (a) NHS England, (b) his Department and (c) NICE. more like this
star this property tabling member constituency Mid Derbyshire remove filter
star this property tabling member printed
Pauline Latham remove filter
star this property uin 57212 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2016-12-20more like thismore than 2016-12-20
star this property answer text <p>The Department has placed no restrictions on patients accessing treatments for advanced (stage 4) melanoma.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published guidance on the following treatments for melanoma. National Health Service commissioners are legally required to fund drugs and treatments recommended by NICE for eligible patients within three months of final guidance.</p><p> </p><table><tbody><tr><td><p>Appraisal number</p></td><td><p>Year of publication</p></td><td><p>Technology/condition</p></td><td><p>Recommendation</p></td></tr><tr><td><p>TA268</p></td><td><p>2012</p></td><td><p>Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA269</p></td><td><p>2012</p></td><td><p>Vemurafenib for locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA319</p></td><td><p>2014</p></td><td><p>Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA321</p></td><td><p>2014</p></td><td><p>Dabrafenib for unresectable or metastatic BRAF V600 mutation‑positive melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA357<sup>1</sup></p></td><td><p>2015</p></td><td><p>Pembrolizumab for advanced melanoma after disease progression with ipilimumab</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA366<sup>1</sup></p></td><td><p>2015</p></td><td><p>Pembrolizumab for advanced melanoma not previously treated with ipilimumab</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA384</p></td><td><p>2016</p></td><td><p>Nivolumab for advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended in line with marketing authorisation.</p></td></tr><tr><td><p>TA396</p></td><td><p>2016</p></td><td><p>Trametinib in combination with dabrafenib for unresectable or metastatic melanoma</p></td><td><p>Recommended in line with marketing authorisation.</p></td></tr><tr><td><p>TA400</p></td><td><p>2016</p></td><td><p>Nivolumab in combination with ipilimumab for advanced melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA410</p></td><td><p>2016</p></td><td><p>Talimogene laherparepvec for unresectable metastatic melanoma</p></td><td><p>Optimised recommendation for talimogene laherparepvec as an option for treating unresectable, regionally or distantly metastatic (Stage IIIB, IIIC or IVM1a) melanoma that has not spread to bone, brain, lung or other internal organs, only if: - treatment with systemically administered immunotherapies is not suitable; and - the company provides talimogene laherparepvec with the discount agreed in the patient access scheme.</p></td></tr><tr><td><p>TA414</p></td><td><p>2016</p></td><td><p>Cobimetinib in combination with vemurafenib for unresectable or metastatic BRAF V600 mutation-positive melanoma</p></td><td><p>At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.</p></td></tr></tbody></table><p><sup>1</sup> pembrolizumab within its licensed indication was appraised across two separate appraisals.</p><p> </p><p>NHS England has advised that it has carefully translated the evidence base on which NICE has based its recommendations of clinical and cost effectiveness into practical clarifications which directly relate to how the recommended drug indication is incorporated into known treatment pathways in use in England.</p><p> </p><p>Each set of clarifications is in keeping with the NICE recommendations within the marketing authorisation of the relevant drug.</p><p> </p><p>The treatment criteria for both Cancer Drugs Fund and baseline-funded drug indications are set out in the National Cancer Drugs Fund List which is available at:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2016/12/national-cdf-list-v1-15.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2016/12/national-cdf-list-v1-15.pdf</a></p>
star this property answering member constituency Oxford West and Abingdon more like this
star this property answering member printed Nicola Blackwood more like this
unstar this property grouped question UIN 57299 more like this
star this property question first answered
less than 2016-12-20T10:28:45.483Zmore like thismore than 2016-12-20T10:28:45.483Z
unstar this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4025
star this property label Biography information for Mrs Pauline Latham more like this
657941
unstar this property registered interest false more like this
star this property date less than 2016-12-13more like thismore than 2016-12-13
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Medical Treatments: Access more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Health, what steps his Department is taking to prevent NHS England from imposing restrictions on patients' access to NICE-approved treatments for melanoma and other conditions; and if he will make a statement. more like this
star this property tabling member constituency Mid Derbyshire remove filter
star this property tabling member printed
Pauline Latham remove filter
star this property uin 57299 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2016-12-20more like thismore than 2016-12-20
star this property answer text <p>The Department has placed no restrictions on patients accessing treatments for advanced (stage 4) melanoma.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published guidance on the following treatments for melanoma. National Health Service commissioners are legally required to fund drugs and treatments recommended by NICE for eligible patients within three months of final guidance.</p><p> </p><table><tbody><tr><td><p>Appraisal number</p></td><td><p>Year of publication</p></td><td><p>Technology/condition</p></td><td><p>Recommendation</p></td></tr><tr><td><p>TA268</p></td><td><p>2012</p></td><td><p>Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA269</p></td><td><p>2012</p></td><td><p>Vemurafenib for locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA319</p></td><td><p>2014</p></td><td><p>Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA321</p></td><td><p>2014</p></td><td><p>Dabrafenib for unresectable or metastatic BRAF V600 mutation‑positive melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA357<sup>1</sup></p></td><td><p>2015</p></td><td><p>Pembrolizumab for advanced melanoma after disease progression with ipilimumab</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA366<sup>1</sup></p></td><td><p>2015</p></td><td><p>Pembrolizumab for advanced melanoma not previously treated with ipilimumab</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA384</p></td><td><p>2016</p></td><td><p>Nivolumab for advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended in line with marketing authorisation.</p></td></tr><tr><td><p>TA396</p></td><td><p>2016</p></td><td><p>Trametinib in combination with dabrafenib for unresectable or metastatic melanoma</p></td><td><p>Recommended in line with marketing authorisation.</p></td></tr><tr><td><p>TA400</p></td><td><p>2016</p></td><td><p>Nivolumab in combination with ipilimumab for advanced melanoma</p></td><td><p>Recommended in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA410</p></td><td><p>2016</p></td><td><p>Talimogene laherparepvec for unresectable metastatic melanoma</p></td><td><p>Optimised recommendation for talimogene laherparepvec as an option for treating unresectable, regionally or distantly metastatic (Stage IIIB, IIIC or IVM1a) melanoma that has not spread to bone, brain, lung or other internal organs, only if: - treatment with systemically administered immunotherapies is not suitable; and - the company provides talimogene laherparepvec with the discount agreed in the patient access scheme.</p></td></tr><tr><td><p>TA414</p></td><td><p>2016</p></td><td><p>Cobimetinib in combination with vemurafenib for unresectable or metastatic BRAF V600 mutation-positive melanoma</p></td><td><p>At the time of appraisal, the technology was not considered to be an appropriate use of NHS resources based on the data available.</p></td></tr></tbody></table><p><sup>1</sup> pembrolizumab within its licensed indication was appraised across two separate appraisals.</p><p> </p><p>NHS England has advised that it has carefully translated the evidence base on which NICE has based its recommendations of clinical and cost effectiveness into practical clarifications which directly relate to how the recommended drug indication is incorporated into known treatment pathways in use in England.</p><p> </p><p>Each set of clarifications is in keeping with the NICE recommendations within the marketing authorisation of the relevant drug.</p><p> </p><p>The treatment criteria for both Cancer Drugs Fund and baseline-funded drug indications are set out in the National Cancer Drugs Fund List which is available at:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2016/12/national-cdf-list-v1-15.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2016/12/national-cdf-list-v1-15.pdf</a></p>
star this property answering member constituency Oxford West and Abingdon more like this
star this property answering member printed Nicola Blackwood more like this
unstar this property grouped question UIN 57212 more like this
star this property question first answered
less than 2016-12-20T10:28:45.56Zmore like thismore than 2016-12-20T10:28:45.56Z
unstar this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
4025
star this property label Biography information for Mrs Pauline Latham more like this
604209
unstar this property registered interest false more like this
star this property date less than 2016-10-17more like thismore than 2016-10-17
star this property answering body
Cabinet Office more like this
star this property answering dept id 53 more like this
star this property answering dept short name Cabinet Office more like this
star this property answering dept sort name Cabinet Office more like this
star this property hansard heading Mining more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Minister for the Cabinet Office, what information his Department holds on the number of employees of mining companies that are registered in the UK and listed on the London Stock Exchange. more like this
star this property tabling member constituency Mid Derbyshire remove filter
star this property tabling member printed
Pauline Latham remove filter
star this property uin 48923 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2016-10-25more like thismore than 2016-10-25
star this property answer text <p>The information requested falls within the responsibility of the UK Statistics Authority. I have asked the Authority to reply.</p> more like this
star this property answering member constituency Kingswood more like this
star this property answering member printed Chris Skidmore more like this
unstar this property grouped question UIN 48924 more like this
star this property question first answered
less than 2016-10-25T09:05:35.44Zmore like thismore than 2016-10-25T09:05:35.44Z
unstar this property answering member
4021
star this property label Biography information for Chris Skidmore more like this
star this property attachment
1
star this property file name PQ 48923 & 48924 V.02.pdf more like this
star this property title UKSA Letter to Member - Mining Company Employees more like this
star this property tabling member
4025
star this property label Biography information for Mrs Pauline Latham more like this
604210
unstar this property registered interest false more like this
star this property date less than 2016-10-17more like thismore than 2016-10-17
star this property answering body
Cabinet Office more like this
star this property answering dept id 53 more like this
star this property answering dept short name Cabinet Office more like this
star this property answering dept sort name Cabinet Office more like this
star this property hansard heading Mining more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Minister for the Cabinet Office, what information his Department holds on the number of mining companies that are registered in the UK. more like this
star this property tabling member constituency Mid Derbyshire remove filter
star this property tabling member printed
Pauline Latham remove filter
star this property uin 48924 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2016-10-25more like thismore than 2016-10-25
star this property answer text <p>The information requested falls within the responsibility of the UK Statistics Authority. I have asked the Authority to reply.</p> more like this
star this property answering member constituency Kingswood more like this
star this property answering member printed Chris Skidmore more like this
unstar this property grouped question UIN 48923 more like this
star this property question first answered
less than 2016-10-25T09:05:35.487Zmore like thismore than 2016-10-25T09:05:35.487Z
unstar this property answering member
4021
star this property label Biography information for Chris Skidmore more like this
star this property attachment
1
star this property file name PQ 48923 & 48924 V.02.pdf more like this
star this property title UKSA Letter to Member - Mining Company Employees more like this
star this property tabling member
4025
star this property label Biography information for Mrs Pauline Latham more like this
751368
unstar this property registered interest false more like this
star this property date less than 2017-07-12more like thismore than 2017-07-12
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Medical Treatments: Innovation more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Health, what funding is available for treatments which have been made available under the Early Access to Medicines Scheme after marketing authorisation but before the publication of NICE guidance. more like this
star this property tabling member constituency Mid Derbyshire remove filter
star this property tabling member printed
Pauline Latham remove filter
star this property uin 4699 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2017-07-20more like thismore than 2017-07-20
star this property answer text <p>The Early Access to Medicines Schemes is a voluntary scheme. Companies are not paid for the medicines they supply into the scheme. However, the Government has recently announced new funding as part of a of a wider package of up to £86 million aimed at addressing barriers to uptake of innovation that were recommended in the Accelerated Access Review. Small to Medium Enterprises with products that meet the requirements for the Early Access to Medicines Scheme will be able to access this funding opportunity. Further announcements will be made on how small businesses can apply for this support. More information can be found at this link:</p><p> </p><p><a href="https://www.gov.uk/government/news/86-million-funding-announced-for-new-medicine-and-technology" target="_blank">https://www.gov.uk/government/news/86-million-funding-announced-for-new-medicine-and-technology</a></p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
unstar this property grouped question UIN 4700 more like this
star this property question first answered
less than 2017-07-20T15:14:36.357Zmore like thismore than 2017-07-20T15:14:36.357Z
unstar this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4025
star this property label Biography information for Mrs Pauline Latham more like this
751369
unstar this property registered interest false more like this
star this property date less than 2017-07-12more like thismore than 2017-07-12
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Medical Treatments: Innovation more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Health, what plans he has to transfer the funding of medicines under the Early Access to Medicines Scheme from pharmaceutical companies to the NHS. more like this
star this property tabling member constituency Mid Derbyshire remove filter
star this property tabling member printed
Pauline Latham remove filter
star this property uin 4700 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2017-07-20more like thismore than 2017-07-20
star this property answer text <p>The Early Access to Medicines Schemes is a voluntary scheme. Companies are not paid for the medicines they supply into the scheme. However, the Government has recently announced new funding as part of a of a wider package of up to £86 million aimed at addressing barriers to uptake of innovation that were recommended in the Accelerated Access Review. Small to Medium Enterprises with products that meet the requirements for the Early Access to Medicines Scheme will be able to access this funding opportunity. Further announcements will be made on how small businesses can apply for this support. More information can be found at this link:</p><p> </p><p><a href="https://www.gov.uk/government/news/86-million-funding-announced-for-new-medicine-and-technology" target="_blank">https://www.gov.uk/government/news/86-million-funding-announced-for-new-medicine-and-technology</a></p> more like this
star this property answering member constituency Winchester more like this
star this property answering member printed Steve Brine more like this
unstar this property grouped question UIN 4699 more like this
star this property question first answered
less than 2017-07-20T15:14:36.603Zmore like thismore than 2017-07-20T15:14:36.603Z
unstar this property answering member
4067
star this property label Biography information for Steve Brine more like this
star this property tabling member
4025
star this property label Biography information for Mrs Pauline Latham more like this
449844
unstar this property registered interest false more like this
star this property date less than 2016-02-02more like thismore than 2016-02-02
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading NHS: Public Relations more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Health, what proportion of the NHS budget was spent on public relations and communications in each of the last five years. more like this
star this property tabling member constituency Mid Derbyshire remove filter
star this property tabling member printed
Pauline Latham remove filter
star this property uin 25430 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2016-02-08more like thismore than 2016-02-08
star this property answer text <p>The Department does not hold the requested information.</p> more like this
star this property answering member constituency North East Bedfordshire more like this
star this property answering member printed Alistair Burt more like this
star this property grouped question UIN
25431 more like this
25432 more like this
star this property question first answered
less than 2016-02-08T12:36:42.66Zmore like thismore than 2016-02-08T12:36:42.66Z
unstar this property answering member
1201
star this property label Biography information for Alistair Burt more like this
star this property tabling member
4025
star this property label Biography information for Mrs Pauline Latham more like this
449841
unstar this property registered interest false more like this
star this property date less than 2016-02-02more like thismore than 2016-02-02
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading NHS: Public Relations more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons remove filter
star this property question text To ask the Secretary of State for Health, how many public relations and communications staff have been hired directly by the NHS in each of the last five years. more like this
star this property tabling member constituency Mid Derbyshire remove filter
star this property tabling member printed
Pauline Latham remove filter
star this property uin 25432 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2016-02-08more like thismore than 2016-02-08
star this property answer text <p>The Department does not hold the requested information.</p> more like this
star this property answering member constituency North East Bedfordshire more like this
star this property answering member printed Alistair Burt more like this
star this property grouped question UIN
25430 more like this
25431 more like this
star this property question first answered
less than 2016-02-08T12:36:42.77Zmore like thismore than 2016-02-08T12:36:42.77Z
unstar this property answering member
1201
star this property label Biography information for Alistair Burt more like this
star this property tabling member
4025
star this property label Biography information for Mrs Pauline Latham more like this